Newly Issued USPSTF Guidelines For Colorectal Cancer Include Complete Line Of Products From Polymedco
CORTLANDT MANOR, N.Y., June 21, 2016 /PRNewswire/ -- Polymedco announced today that its OC-Auto® family of FIT products and Epi proColon® (Epigenomics) blood test for colorectal cancer screening have both been classified as Grade A recommended screening tests by the United States Preventative Services Task Force (USPSTF) in the recommendation statement released on June 21, 2016. Grade A recommendation is defined as: "The USPSTF recommends the service. There is high certainty that the net benefit is substantial." The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.
The USPSTF states the OC-Auto {OC FIT-CHEK family of FITs (Polymedco)}which include the OC-Light and the OC-Autohave the best test performance characteristics (ie, highest sensitivity and specificity).
The USPSTF names Epi proColon ("SEPT9 DNA test") as one of several screening tests for the detection of early-stage colorectal cancer.
According to the USPSTF, screening for colorectal cancer is a substantially underused preventive health strategy in the United States. In addition, there are no empirical data to suggest that any of the strategies provide a greater net benefit. Accordingly, the best screening test is the one that gets done, and the USPSTF concludes that maximizing the total proportion of the eligible population that receives screening will result in the greatest reduction in colorectal cancer deaths.
Polymedco believes that the new USPSTF guidelines will result in higher screening rates with OC-Auto® and Epi proColon® modalities and supports the American Cancer Society and NCCRT's combined goal of achieving 80% of the population screened by 2018.
About OC-Auto®: Polymedco is the leader in FIT testing, with the first FDA cleared automated FIT analyzer, OC-Auto®, the high throughput automated FIT analyzer OC-Auto® Sensor Diana, and the recently cleared OC-Light® S FIT manual point of care test. Single sample, no dietary restrictions, ease of use, and customized patient packs all increase patient compliance.
About Epi proColon®: Epi proColon is an in-vitro PCR (polymerase chain reaction) assay for the qualitative detection of Septin9 gene methylation in DNA isolated from the patient's plasma. Cytosine residues of the Septin9 gene are methylated in colorectal cancer tissue, but not in normal colon mucosa. This tumor-specific methylation pattern can be used to detect cell-free DNA shed into the blood stream by tumor cells. Detection of colorectal cancer-derived DNA in blood plasma using the Septin9 methylation biomarker has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States by Polymedco CDP, LLC.
About Polymedco: Since 1980, Polymedco has evolved into a leading manufacturer, marketer, and distributor in the clinical laboratory marketplace. Polymedco supplies clinical diagnostic test kits that are specialized in hematology and cancer screening. We are a world leader in non-invasive colorectal cancer screening technology, providing the new standard of care with the OC-Auto® and OC-Light® product lines.
Polymedco Cancer Diagnostic Products, LLC.
510 Furnace Dock Road
Cortlandt Manor, NY 10567 USA
Telephone: 800-431-2123
Facsimile: 914-739-5890
OC-Auto and OC-Light are Registered Trademarks of Polymedco CDP, LLC.
Epi proColon is a Registered Trademark of Epigenomics, AG
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/newly-issued-uspstf-guidelines-for-colorectal-cancer-include-complete-line-of-products-from-polymedco-300288003.html
SOURCE Polymedco
